Evidence map›Paper›PMID 35409719›Full record

ArticleInternational journal of environmental research and public health2022

Development and Feasibility of an Inpatient Cancer-Related Sarcopenia Pathway at a Major Cancer Centre.

Jenelle Loeliger, Lara Edbrooke, Robin M Daly, Jane Stewart, Lucy Bucci, Carmen Puskas, Marnie Fitzgerald, Brenton J Baguley, Nicole Kiss

Abstract read
In one paragraph

Article in International journal of environmental research and public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Triage tools to inform the prioritisation of physical health services following a diagnosis of cancer: a scoping review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jenelle LoeligerNutrition & Speech Pathology Department, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.ORCID 0000-0003-4423-109X
Lara EdbrookeDepartment of Health Services Research, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.ORCID 0000-0002-4149-5578
Robin M DalyInstitute for Physical Activity and Nutrition, Deakin University, Geelong, VIC 3220, Australia.ORCID 0000-0002-9897-1598
Jane StewartNutrition & Speech Pathology Department, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.ORCID 0000-0002-0183-4379
Lucy BucciPhysiotherapy & Occupational Therapy Department, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.
Carmen PuskasNutrition & Speech Pathology Department, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.
Marnie FitzgeraldPhysiotherapy & Occupational Therapy Department, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.
Brenton J BaguleyInstitute for Physical Activity and Nutrition, Deakin University, Geelong, VIC 3220, Australia.ORCID 0000-0003-3974-8107
Nicole KissInstitute for Physical Activity and Nutrition, Deakin University, Geelong, VIC 3220, Australia.ORCID 0000-0002-6476-9834

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer-related sarcopenia is a complex condition; however, no cancer-specific clinical model is available to guide clinical practice. This study aims to (1) develop an evidence-based care pathway for the management of cancer-related sarcopenia ("sarc-pathway") and (2) pilot test the feasibility (reach, intervention fidelity, patient and clinician acceptability) of the sarc-pathway in an inpatient cancer ward. The sarc-pathway was developed using a care pathway format and informed by the current literature. Patients admitted to a 32-bed inpatient cancer ward were recruited to receive sarc-pathway care and the feasibility outcomes were assessed. Of the 317 participants admitted, 159 were recruited over 3.5-months (median age 61 years; 56.0% males). Participant consent was high (99.4% of those approached) and 30.2% were at risk of/had sarcopenia. The sarc-pathway screening, assessment and treatment components were delivered as intended; however, low completion of clinical assessment measures were observed for muscle mass (bioimpedance spectroscopy, 20.5%) and muscle function (5-times chair stand test, 50.0%). The sarc-pathway was demonstrated to be acceptable to patients and multidisciplinary clinicians. In an inpatient cancer ward, the sarc-pathway is a feasible and acceptable clinical model and method to deliver and adhere to the sarcopenia clinical parameters specified, albeit with further exploration of appropriate clinical assessment measures.

Indexed as

NeoplasmsSarcopeniaAgedCross-Sectional StudiesFeasibility StudiesFemaleGeriatric AssessmentHumansInpatientsMaleMass ScreeningMiddle AgedSurveys and Questionnairescancercare pathwayexerciselow muscle massmalnutritionmultimodalnutritionsarcopenia

Identifiers

PMID35409719
PMCPMC8997788

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.